Sarepta Therapeutics Inc
NASDAQ: SRPT
$114.23
+$3.73 (+3.4%)
Closing Price on November 22, 2024
SRPT Articles
The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford, Kinder Morgan, Pandora Media, Procter &...
Published:
Last Updated:
Sarepta Therapeutics shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy trial.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Published:
Last Updated:
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron and Noble Energy.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, U.S. Steel and Walmart.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth and Wayfair.
Published:
Last Updated:
A new RBC report is reasonably positive on the biotech sector for the coming year. These eight top picks for 2018 all have the potential for big upside moves.
Published:
Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA.
Published:
Last Updated:
Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.
Published:
Last Updated:
Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a late-breaking session at the World Muscle Society...
Published:
Last Updated:
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s...
Published:
Last Updated:
courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull market is...
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.
Published:
Last Updated: